TET2 and acute myeloid leukemia: For example, SF3B1 mutations were substantially associated with a higher risk of MDS, while SRSF2 mutations were substantially associated with all myeloid neoplasm subtypes, with SRSF2/TET2 comutated cases were more likely to develop MDS and SRSF2/IDH2 comutated cases were more likely to develop AML.